ReviewTargeted oncology2010
Molecular markers in gliomas: impact for the clinician.
Review in Targeted oncology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- MRI features can predict EGFR expression in lower grade gliomas: A voxel-based radiomic analysis.European radiology · 2018Trial
- Crosstalk between CD180-overexpression macrophages and glioma cells worsens patient survival through malignant phenotype promotion and immunosuppressive regulation.Molecular medicine (Cambridge, Mass.) · 2024Article
- MMP-1, UCH-L1, and 20S Proteasome as Potential Biomarkers Supporting the Diagnosis of Brain Glioma.Biomolecules · 2022Article
- Article
- High expression of GPNMB indicates an unfavorable prognosis in glioma: Combination of data from the GEO and CGGA databases and validation in tissue microarray.Oncology letters · 2020Article
- Twenty Metabolic Genes Based Signature Predicts Survival of Glioma Patients.Journal of Cancer · 2020Article
- Practical Bioinformatic DNA-Sequencing Pipeline for Detecting Oncogene Amplification and EGFRvIII Mutational Status in Clinical Glioblastoma Samples.The Journal of molecular diagnostics : JMD · 2019Article
- The future of high-grade glioma: Where we are and where are we going.Surgical neurology international · 2015Article
- Advances in genetic and epigenetic analyses of gliomas: a neuropathological perspective.Journal of neuro-oncology · 2014Review
- Molecular biology of high-grade gliomas: what should the clinician know?Chinese journal of cancer · 2014Review
- Expression of p53, epidermal growth factor receptor, Ki-67 and OOncology letters · 2013Article
- The value of temozolomide in combination with radiotherapy during standard treatment for newly diagnosed glioblastoma.Journal of neuro-oncology · 2013Article
- Success at last: a molecular factor that informs treatment.Current oncology reports · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Over the last decade, understanding of glioma on a molecular level has greatly expanded. However, optimal incorporation of molecular markers into clinical care is controversial. We briefly review the potential utility of molecular stratification in refining histologic diagnosis, prognosis, and treatment decisions, focussing on 1p/19q co-deletion, MGMT promoter methylation, EGFR mutations, and IDH mutation. The most recently discovered IDH mutation is a striking example of a rapid implementation of a molecular marker for prognostication into common clinical use.
Indexed as
Identifiers
20809335What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.